DAXXIFY® (daxibotulinumtoxinA-lanm)

DAXXIFY is made by Revance Therapeutics and is the most recently approved of the three neurotoxins the clinic carries. The FDA approved it on September 7, 2022, for temporary improvement of moderate to severe glabellar lines (frown lines); it was Revance's first FDA-approved product. Like BOTOX Cosmetic and Xeomin, its active ingredient is a form of botulinum toxin type A, a protein that blocks the nerve signals that make a muscle contract, temporarily reducing that muscle's activity. What sets DAXXIFY apart is its formulation: the toxin is paired with a proprietary synthetic peptide, which the manufacturer calls Peptide Exchange Technology, used to stabilize the molecule instead of the human blood-derived protein (human serum albumin) used to stabilize some other neuromodulators; DAXXIFY's manufacturer states the product contains no human serum albumin or animal-derived ingredients. In August 2023 the FDA also approved DAXXIFY to treat cervical dystonia, a neurological muscle condition, its first approved use beyond cosmetics.